> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 2 Drug Substances Excluded from Compounding Listing
- URL: https://www.fdaweb.com/2-drug-substances-excluded-from-compounding-listing/
- Published: 2019-03-04T12:00:00.000Z
- Updated: 2026-09-15T01:09:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143512

*Federal Register* notice: FDA has identified two bulk drug substances that it has considered and is not including on its drug compounding bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need. The affected drugs are nicardipine hydrochloride and vasopressin. Additional bulk drug substances nominated by the public for inclusion on the list are currently under consideration and will be the subject of future notices. To view the notices, click [here](https://www.govinfo.gov/content/pkg/FR-2019-03-04/pdf/2019-03810.pdf?ref=fdaweb.com).